Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marshall Edwards, an oncology company, has filed an application with the FDA for an investigative new drug approval to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine.
Subscribe to our email newsletter
The investigative new drug (IND) application is to enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.
Triphendiol is an investigational drug in the Marshall Edwards oncology drug pipeline, currently being developed as an orally-delivered chemosensitizing agent, intended for use in conjunction with standard chemotoxic anticancer drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and melanoma.